IL4I1 and B-cell non-Hodgkin lymphoma: were the first to propose that the novel immunosuppressive enzyme IL4I1, which is produced by the neoplastic cells of several B-cell lymphomas and by tumor-associated macrophages, is a prognostic biomarker and therapeutic target in cancer (54).